Akari Therapeutics PLC (NASDAQ:AKTX) held an R&D day on 24 April 2017, at which it announced the interim results from the Phase II clinical trial of Coversin for paroxysmal nocturnal hemoglobinuria (PNH). The four patients who completed the study met the primary endpoint of hemolysis within 1.8x the upper limit of normal (ULN), with the average at 1.5x ULN, which is considered optimal control similar to Soliris. Additionally, it announced the initiation of an atypical hemolytic uremic syndrome (aHUS) Phase II in Q217 and two new programs: bullous pemphigoid (BP), and mucous membrane pemphigoid (MMP).
Same results as Soliris from a once-daily injection
The average rate of hemolysis achieved for the patients in the report of 1.5x ULN is similar to the pivotal trials of Soliris (1.5x and 1.3x), and one of the patients from the Coversin trial was not completely dose optimized by the time of the report. No patients required blood transfusions, whereas approximately half would be expected to require transfusions if untreated. This was accomplished with once-daily subcutaneous injections, a significant convenience improvement over biweekly intravenous injections given by a provider, as in the case of Soliris.
To read the entire report Please click on the pdf File Below